Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Sr.VP Bus.Dev.Alliance Mgmt. | November 18, 2019 | November 21, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RIGEL PHARMACEUTICALS INC
Report date November 18, 2019 · Filed November 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.49 · Expires 2028-01-24 | Direct | 43,750 |
Reported balance
After 2019-11-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-18 · Grant · Acquired 43,750 · Balance 43,750 F1: The reporting person was granted a performance based option to purchase 43,750 shares of common stock on January 24, 2018. Thus, the exercise price of this option is $4.49 (the closing price of the issuer's common stock on Nasdaq the day prior to the date of grant). In light of the performance-based vesting condition of this grant, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 18, 2019, it was determined that the performance metric had been met. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was granted a performance based option to purchase 43,750 shares of common stock on January 24, 2018. Thus, the exercise price of this option is $4.49 (the closing price of the issuer's common stock on Nasdaq the day prior to the date of grant). In light of the performance-based vesting condition of this grant, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 18, 2019, it was determined that the performance metric had been met.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2019 Filed Nov 21, 2019 01:20 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 43,750 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001179110-19-011946 · edgar.xml · derivative · entry 1 Lasaga Joseph · CIK 0001686916 · Sr.VP Bus.Dev.Alliance Mgmt. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock · 43,750 shares Expires 2028-01-24 F1 · derivative.exercise_price: The reporting person was granted a performance based option to purchase 43,750 shares of common stock on January 24, 2018. Thus, the exercise price of this option is $4.49 (the closing price of the issuer's common stock on Nasdaq the day prior to the date of grant). In light of the performance-based vesting condition of this grant, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 18, 2019, it was determined that the performance metric had been met. F1 · derivative.exercise_date: The reporting person was granted a performance based option to purchase 43,750 shares of common stock on January 24, 2018. Thus, the exercise price of this option is $4.49 (the closing price of the issuer's common stock on Nasdaq the day prior to the date of grant). In light of the performance-based vesting condition of this grant, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 18, 2019, it was determined that the performance metric had been met. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 23:25 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 43,750 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001179110-19-004210 · edgar.xml · derivative · entry 1 Lasaga Joseph · CIK 0001686916 · Sr.VP Bus.Dev.Alliance Mgmt. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock · 43,750 shares Expires 2028-01-24 F1 · derivative.exercise_date: On January 24, 2018, the reporting person was granted a performance based option to purchase 43,750 shares of common stock based on a specific performance metric. On March 20, 2019, it was determined that the performance metric had been met. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 23:53 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001179110-19-000939 · edgar.xml · derivative · entry 1 Lasaga Joseph · CIK 0001686916 · Sr.VP Bus.Dev.Alliance Mgmt. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:51 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001179110-18-006682 · edgar.xml · derivative · entry 1 Lasaga Joseph · CIK 0001686916 · VP Bus. Dev.& Alliance Mgmt. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-02-02 F1 · derivative.exercise_date: On February 2, 2017 the reporting person was granted an option to purchase 25,000 shares of common stock. The option vested based on the Compensation Committee's determination that one or more pre-established performance conditions had been achieved. On May 9, 2018, the Compensation Committee determined that the performance conditions had been achieved, resulting in full vesting of the option. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 23:38 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 87,500 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001179110-18-001145 · edgar.xml · derivative · entry 1 Lasaga Joseph · CIK 0001686916 · VP Bus. Dev.& Alliance Mgmt. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2028-01-24 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2018. Read SEC document |
| February 02, 2017 Filed Feb 7, 2017 00:33 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001179110-17-001828 · edgar.xml · derivative · entry 1 Lasaga Joseph · CIK 0001686916 · VP Bus. Dev.& Alliance Mgmt. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-02-02 F1 · derivative.exercise_date: The shares vest monthly over four (4) years from January 1, 2017. Read SEC document |
| October 10, 2016 Filed Oct 12, 2016 00:51 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001179110-16-030657 · edgar.xml · derivative · entry 1 Lasaga Joseph · CIK 0001686916 · VP Bus. Dev.& Alliance Mgmt. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2026-10-10 F1 · derivative.exercise_date: Common Stock subject to the Option shall vest over a four-year term, with one-fourth of the shares subject to the Option vesting on October 10, 2017, and 1/48th of the shares subject to the Option vesting monthly thereafter, subject to the Continuous Service (as defined in the Plan) to the Company through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.